Cargando…

Health-Related Quality of Life and Health Utility Values in Beta Thalassemia Major Patients Receiving Different Types of Iron Chelators in Iran

Background: Thalassemia is a chronic, inherited blood disorder, which in its most severe form, causes life-threatening anemia. Thalassemia patients not only engage with difficulties of blood transfusion and iron chelating therapy but also have some social challenges and health threatening factors. T...

Descripción completa

Detalles Bibliográficos
Autores principales: Seyedifar, Meysam, Dorkoosh, Farid Abedin, Hamidieh, Amir Ali, Naderi, Majid, Karami, Hossein, Karimi, Mehran, Fadaiyrayeny, Masoomeh, Musavi, Masoumeh, Safaei, Sanaz, Ahmadian-Attari, Mohammad Mahdi, Hadjibabaie, Molouk, Cheraghali, Abdol Majid, Akbari Sari, Ali
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Tehran University of Medical Sciences, Hematology-Oncology and Stem Cell Transplantation Research Center 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5139942/
https://www.ncbi.nlm.nih.gov/pubmed/27928477
_version_ 1782472335414001664
author Seyedifar, Meysam
Dorkoosh, Farid Abedin
Hamidieh, Amir Ali
Naderi, Majid
Karami, Hossein
Karimi, Mehran
Fadaiyrayeny, Masoomeh
Musavi, Masoumeh
Safaei, Sanaz
Ahmadian-Attari, Mohammad Mahdi
Hadjibabaie, Molouk
Cheraghali, Abdol Majid
Akbari Sari, Ali
author_facet Seyedifar, Meysam
Dorkoosh, Farid Abedin
Hamidieh, Amir Ali
Naderi, Majid
Karami, Hossein
Karimi, Mehran
Fadaiyrayeny, Masoomeh
Musavi, Masoumeh
Safaei, Sanaz
Ahmadian-Attari, Mohammad Mahdi
Hadjibabaie, Molouk
Cheraghali, Abdol Majid
Akbari Sari, Ali
author_sort Seyedifar, Meysam
collection PubMed
description Background: Thalassemia is a chronic, inherited blood disorder, which in its most severe form, causes life-threatening anemia. Thalassemia patients not only engage with difficulties of blood transfusion and iron chelating therapy but also have some social challenges and health threatening factors. There are some reports on quality of life in thalassemia patients around the world from southeast of Asia to Italy in Europe and United States. In this study, we tried to evaluate and compare Health Related Quality of life (HRQoL) and the health utility in beta thalassemia major patients receiving different types of iron chelators and living in different socio-economical situations. Subjects and Methods: EQ-5D-3L accompanied by a Visual Analogue Scale (VAS) questionnaire was used. The respondents were patients with beta thalassemia major that were at least 12 years old selected from 3 provinces of Sistan-Blouchestan, Fars and Mazandaran. Comorbidities including heart complication, Diabetes Mellitus and Hepatitis and also types of iron chelators (oral, injection, combination of both) were also asked. Cross tab and ANOVA analysis conducted to evaluate each dimension score and health utility differences between provinces, iron chelation methods, comorbidities, age group and gender. Results: 528 patients answered the questionnaires. The health utility of patients that received oral iron chelator were 0.87 ± .01 for oral iron chelators versus 0.81 ± .01 for injection dosage form (p<0.05). Increase in age was accompanied by decrease in health utility. Females faced more usual activity problems, anxiety and depression. Heart problems were more prevalent in males. Conclusion: This study suggests that the quality of life of beta thalassemia major patients is dependent on type of iron chelation treatment which they received, the gender they have, the comorbidities they suffer and socio-economical situations they live in.
format Online
Article
Text
id pubmed-5139942
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher Tehran University of Medical Sciences, Hematology-Oncology and Stem Cell Transplantation Research Center
record_format MEDLINE/PubMed
spelling pubmed-51399422016-12-07 Health-Related Quality of Life and Health Utility Values in Beta Thalassemia Major Patients Receiving Different Types of Iron Chelators in Iran Seyedifar, Meysam Dorkoosh, Farid Abedin Hamidieh, Amir Ali Naderi, Majid Karami, Hossein Karimi, Mehran Fadaiyrayeny, Masoomeh Musavi, Masoumeh Safaei, Sanaz Ahmadian-Attari, Mohammad Mahdi Hadjibabaie, Molouk Cheraghali, Abdol Majid Akbari Sari, Ali Int J Hematol Oncol Stem Cell Res Original Article Background: Thalassemia is a chronic, inherited blood disorder, which in its most severe form, causes life-threatening anemia. Thalassemia patients not only engage with difficulties of blood transfusion and iron chelating therapy but also have some social challenges and health threatening factors. There are some reports on quality of life in thalassemia patients around the world from southeast of Asia to Italy in Europe and United States. In this study, we tried to evaluate and compare Health Related Quality of life (HRQoL) and the health utility in beta thalassemia major patients receiving different types of iron chelators and living in different socio-economical situations. Subjects and Methods: EQ-5D-3L accompanied by a Visual Analogue Scale (VAS) questionnaire was used. The respondents were patients with beta thalassemia major that were at least 12 years old selected from 3 provinces of Sistan-Blouchestan, Fars and Mazandaran. Comorbidities including heart complication, Diabetes Mellitus and Hepatitis and also types of iron chelators (oral, injection, combination of both) were also asked. Cross tab and ANOVA analysis conducted to evaluate each dimension score and health utility differences between provinces, iron chelation methods, comorbidities, age group and gender. Results: 528 patients answered the questionnaires. The health utility of patients that received oral iron chelator were 0.87 ± .01 for oral iron chelators versus 0.81 ± .01 for injection dosage form (p<0.05). Increase in age was accompanied by decrease in health utility. Females faced more usual activity problems, anxiety and depression. Heart problems were more prevalent in males. Conclusion: This study suggests that the quality of life of beta thalassemia major patients is dependent on type of iron chelation treatment which they received, the gender they have, the comorbidities they suffer and socio-economical situations they live in. Tehran University of Medical Sciences, Hematology-Oncology and Stem Cell Transplantation Research Center 2016-10-01 /pmc/articles/PMC5139942/ /pubmed/27928477 Text en Copyright : © International Journal of Hematology-Oncology and Stem Cell Research & Tehran University of Medical Sciences This is an Open Access article distributed under the terms of the Creative Commons Attribution License, (http://creativecommons.org/licenses/by/3.0/) which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Original Article
Seyedifar, Meysam
Dorkoosh, Farid Abedin
Hamidieh, Amir Ali
Naderi, Majid
Karami, Hossein
Karimi, Mehran
Fadaiyrayeny, Masoomeh
Musavi, Masoumeh
Safaei, Sanaz
Ahmadian-Attari, Mohammad Mahdi
Hadjibabaie, Molouk
Cheraghali, Abdol Majid
Akbari Sari, Ali
Health-Related Quality of Life and Health Utility Values in Beta Thalassemia Major Patients Receiving Different Types of Iron Chelators in Iran
title Health-Related Quality of Life and Health Utility Values in Beta Thalassemia Major Patients Receiving Different Types of Iron Chelators in Iran
title_full Health-Related Quality of Life and Health Utility Values in Beta Thalassemia Major Patients Receiving Different Types of Iron Chelators in Iran
title_fullStr Health-Related Quality of Life and Health Utility Values in Beta Thalassemia Major Patients Receiving Different Types of Iron Chelators in Iran
title_full_unstemmed Health-Related Quality of Life and Health Utility Values in Beta Thalassemia Major Patients Receiving Different Types of Iron Chelators in Iran
title_short Health-Related Quality of Life and Health Utility Values in Beta Thalassemia Major Patients Receiving Different Types of Iron Chelators in Iran
title_sort health-related quality of life and health utility values in beta thalassemia major patients receiving different types of iron chelators in iran
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5139942/
https://www.ncbi.nlm.nih.gov/pubmed/27928477
work_keys_str_mv AT seyedifarmeysam healthrelatedqualityoflifeandhealthutilityvaluesinbetathalassemiamajorpatientsreceivingdifferenttypesofironchelatorsiniran
AT dorkooshfaridabedin healthrelatedqualityoflifeandhealthutilityvaluesinbetathalassemiamajorpatientsreceivingdifferenttypesofironchelatorsiniran
AT hamidiehamirali healthrelatedqualityoflifeandhealthutilityvaluesinbetathalassemiamajorpatientsreceivingdifferenttypesofironchelatorsiniran
AT naderimajid healthrelatedqualityoflifeandhealthutilityvaluesinbetathalassemiamajorpatientsreceivingdifferenttypesofironchelatorsiniran
AT karamihossein healthrelatedqualityoflifeandhealthutilityvaluesinbetathalassemiamajorpatientsreceivingdifferenttypesofironchelatorsiniran
AT karimimehran healthrelatedqualityoflifeandhealthutilityvaluesinbetathalassemiamajorpatientsreceivingdifferenttypesofironchelatorsiniran
AT fadaiyrayenymasoomeh healthrelatedqualityoflifeandhealthutilityvaluesinbetathalassemiamajorpatientsreceivingdifferenttypesofironchelatorsiniran
AT musavimasoumeh healthrelatedqualityoflifeandhealthutilityvaluesinbetathalassemiamajorpatientsreceivingdifferenttypesofironchelatorsiniran
AT safaeisanaz healthrelatedqualityoflifeandhealthutilityvaluesinbetathalassemiamajorpatientsreceivingdifferenttypesofironchelatorsiniran
AT ahmadianattarimohammadmahdi healthrelatedqualityoflifeandhealthutilityvaluesinbetathalassemiamajorpatientsreceivingdifferenttypesofironchelatorsiniran
AT hadjibabaiemolouk healthrelatedqualityoflifeandhealthutilityvaluesinbetathalassemiamajorpatientsreceivingdifferenttypesofironchelatorsiniran
AT cheraghaliabdolmajid healthrelatedqualityoflifeandhealthutilityvaluesinbetathalassemiamajorpatientsreceivingdifferenttypesofironchelatorsiniran
AT akbarisariali healthrelatedqualityoflifeandhealthutilityvaluesinbetathalassemiamajorpatientsreceivingdifferenttypesofironchelatorsiniran